Drug Trial Radar · NCT07783269
A Basket Study of CTA313 in Participants With Active Autoimmune Diseases
Last checked: Nov 20, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
81
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Jun 2029
Study completion Sep 2029
Sponsor
- Lead sponsor
- Imviva BioIndustry
- Sponsor type
- Industry
- First posted
- Aug 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of the ALLNEW clinical trial is to learn if CTA313 UCART is safe and effective for patients with immune mediated disorders. Participants with SLE, pMS and AIE between the ages of 18 and 75 will be eligible to participate. Participants will receive one infusion of CTA313 on Day 0. During the Dose Confirmation portion, cohorts will be independently evaluated for safety and to establish the RP2D of CTA313. During the Cohort Expansion portion of the study patients will be evaluated to further confirm the efficacy and safety of CTA313. Patients will be followed for up to 24 months in this study and will be required to enroll under a separate long term follow up protocol to be followed for up to 15 years.
Conditions
- Systemic Lupus Erthematosus (SLE)
- Progressive Multiple Sclerosis (PMS)
- Autoimmune Encephalitis
Interventions
CTA313 UCAR T Cell InfusionDrug
CAR T cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety ProfileTime frame: 24 months
- RP2D DeterminationTime frame: 24 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.